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Introduction.Levonorgestrel a synthetic progestagen used for endometriosis, dysmenorrhea and 
emergency contraception, is quickly and completely absorbed in the digestive tract. levonorgestrel 
is predominantly metabolised through hepatic routes that utilise the CYP3A system (CYP3A4 and 
CYP3A5). 
Objective.This study aimed to evaluate the association between variant alleles of CYP3A4*1B and 
CYP3A5*3 polymorphisms and the pharmacokinetics of levonorgestrel.
Materials and methods. A group of 17 adult female healthy volunteers who signed an informed 
consent were genotyped for CYP3A4 and CYP3A5 through PCR-RFLP. Volunteers were submitted 
to pharmacokinetic analysis where, after a 12-hour overnight fast, they received a single oral dose 
of 0.75 mg of levonorgestrel. Serial blood samples were obtained (0 to 24 hours), and levonorgestrel 
concentrations were determined by UPLC-MS/MS to determine pharmacokinetic parameters. The 
procedures employed herein were performed according to the Declaration of Helsinki and Good Clinical 
Practices standards.
Results. Observed genotype frequencies in the studied group for CYP3A4*1B were 11.8% for *1B/*1B, 
5.8% for *1/*1B and 82.4% for *1/*1. CYP3A5*3 frequencies were 70.5% for *3/*3, 23.5% for *1/*3 and 
6.5% for *1/*1. A high pharmacokinetic variability between volunteers was observed, but no statistical 
association of pharmacokinetic parameters was found within the studied CYP3A4/5 polymorphisms.
Conclusions. Genetic polymorphisms could be important factors in determining inter-patient variability 
in plasma levonorgestrel concentrations, which in this study were not significantly associated with the 
presence of CYP3A4*1B and CYP3A5*3 polymorphisms. Therefore, due to the significant inter-patient 
variability that we observed during the course of this study, it is necessary to carry out studies with 
larger number of volunteers.  
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Influencia de polimorfismos genéticos de CYP3A4/5 en la farmacocinética de levonorgestrel: 
estudio piloto
Introducción. El levonorgestrel, un progestágeno sintético usado para endometriosis, dismenorrea 
y anticoncepción de emergencia, es rápida y completamente absorbido en el tubo digestivo. Su 
metabolismo es principalmente hepático, mediante las enzimas CYP3A4 y CYP3A5. 
Objetivo. El presente estudio tuvo como objetivo evaluar la asociación entre la farmacocinética de 
levonorgestrel y las variantes alélicas de CYP3A4*1B y CYP3A5*3.
Materiales y métodos. En un grupo de 17 mujeres adultas sanas, que firmaron un consentimiento 
informado, se practicó genotipificación para CYP3A4*1B y CYP3A5*3 mediante PCR. Posteriormente, 
las voluntarias fueron sometidas a un estudio farmacocinético donde, luego de 12 horas de ayuno, 
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recibieron una dosis de 0,75 mg de levonorgestrel. Se extrajeron muestras sanguíneas seriadas 
(0 a 24 horas) y se determinaron las concentraciones de levonorgestrel mediante un método validado 
de UPLC-ms/ms, para luego obtener los parámetros farmacocinéticos. Todos los procedimientos 
consideraron los aspectos éticos de la Declaración de Helsinki y las buenas prácticas clínicas. 
Resultados. Las frecuencias genotípicas observadas para el grupo de estudio fueron 11,8 % para 
*1B/*1B; 5,8 % para *1/*1B, y 82,4 % para *1/*1 de CYP3A4*1B. Para CYP3A5*3, las frecuencias 
genotípicas fueron 70,5 % para *3/*3; 23,5 % para *1/*3, y 6,5 % para *1/*1. Se observa una interesante 
variabilidad entre las voluntarias que sugiere una relación con las variantes genéticas CYP3A, pero 
que no permite establecer una asociación estadísticamente significativa, presumiblemente debido al 
bajo número de individuos homocigotos mutados de CYP3A4 y silvestres de CYP3A5.
Conclusiones. Los polimorfismos genéticos podrían ser factores relevantes en la determinación 
de la variabilidad entre pacientes en las concentraciones plasmáticas de levonorgestrel, lo cual, sin 
embargo, no pudo ser establecido estadísticamente en este estudio. Por lo tanto, resulta necesario 
continuar este tipo de estudios con mayor número de voluntarios para establecer una asociación entre 
la variabilidad observada y la presencia de estos polimorfismos. 
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doi: http://dx.doi.org/10.7705/biomedica.v32i4.789
Corresponding author:
Iván Saavedra, Centro de Investigaciones Farmacológicas y 
Toxicológicas, Facultad de Medicina, Universidad de Chile, 
Santiago de Chile, Chile. 
Teléfono: (562) 681 7756; fax: (562) 682 2406
isaavedr@med.uchile.cl
Recibido: 05/10/11; aceptado:24/07/12
Cytochrome P45 3A (CYP3A) enzymes constitute 
approximately 50% of the total hepatic amount 
of cytochrome P450 enzymes, and they are 
responsible for the metabolism of about half of 
the most commonly used drugs. This indicates 
that CYP3A enzymes present an unusually low 
substrate-specificity, which makes exposes them to 
reversible or irreversible inhibition by a wide variety 
of drugs (1-3). Due to this remarkable role on drug 
metabolism, it is important to know what parameters 
determine CYP3A activity. Moreover, there is 
evidence of significant inter-individual variability in 
the metabolic profile of CYP3A, which explains how 
the in vivo metabolism of CYP3A substrates may 
differ between individuals by up to a factor of ten in 
certain instances (4). CYP3A enzyme expression is 
induced by numerous drugs such as phenobarbital, 
rifampicin, dexamethasone and phenytoin. Known 
inhibitors of these enzymes include imidazole, 
antimycotics, antibiotics (such as macrolides) and 
some compounds in grapefruit juice (5).
Levonorgestrel, a synthetic progestagen derived 
from 19-nortestosterone, has been used for 
decades and is combined with ethynilestradiol as a 
contraceptive; this formulation has also been used 
for endometriosis, dysmenorrhea and emergency 
contraception (6-8). Levonorgestrel is quickly and 
completely absorbed in the digestive tract and is 
therefore is not affected by the first hepatic pass. 
Thus, levonorgestrel has a bioavailability near 
100%. After a single oral dose of 0.75 mg, the 
highest average plasmatic concentrations are 14 
ng/mL after approximately 1.6 hours. (9).The active 
principle circulates in blood and is bound mainly 
to albumin and sexual hormone-binding globulin. 
The levonorgestrel half-life is approximately 20 
to 30 hours. The active drug and its metabolites 
are excreted from the organism predominantly 
through the renal structure, though small amounts 
appear in faeces (10). Its metabolism is mainly 
hepatic, through the CYP3A system (CYP3A4 and 
CYP3A5). The CYP3A system is also responsible 
for the oxidative metabolism of endogenous 
steroids, such as oestrogens, progesterone and 
endogenous androgens (11-13).
There is not enough published data regarding 
the effects that CYP3A4*1B and CYP3A5*3 
polymorphisms may have on the pharmacokinetic 
parameters of levonorgestrel in healthy volunteers. 
It is plausible that these polymorphisms may 
significantly inhibit levonorgestrel metabolism, 
which in turn raises the maximum plasmatic 
concentration (Cmax), half-life (t1/2), AUC 0t, y AUC 
0∞ and elimination constant (Kel)
This study aimed to evaluate the association 
between variant alleles of CYP3A4*1B and 
CYP3A5*3 polymorphisms and the pharmacokinetics 
of levonorgestrel in a subgroup of healthy Chilean 
volunteers.
Materials and methods
Volunteers
A group of 17 adult female Chilean healthy 
volunteers, whose ages ranged from 18 to 50 years 
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old, were chosen. Volunteers signed a written 
informed consent. Subsequently, a complete 
physical examination and clinical laboratory 
analysis were performed. This evaluation included 
hemogram, HSR (hematic sedimentation rate), 
urine analysis, HIV test, glycaemia, uraemia, 
proteinaemia, alkaline phosphatase, total bilirubin, 
ALT, AST and creatinine (table 1), in addition 
to a pregnancy test based on human chorionic 
gonadotropin hormone levels.
The inclusion criteria were as follows:
Healthy Latin American women, between 18 •	
and 50 years of age.
Not pregnant or breast-feeding.•	
Non-smokers, and neither drug users nor •	
alcohol consumers.
Without known drug allergies.•	
Without concomitant therapies; neither •	
hormonal nor psychotropic treatment and with 
no history of consuming other drugs for at least 
three months prior to starting the study.
Patients without any gynaecologic or malignant •	
illness.
With normal laboratory exams and declared •	
suitable for the study by the presiding medical 
doctor.
Genotype analysis
Subjects were genotyped for CYP3A4 and 
CYP3A5 using the volunteer’s peripheral blood 
samples and were isolated according to the DNA 
of the peripheral leukocytes, as defined by the 
laboratory’s protocol. Polymerase Chain Reaction 
(PCR) was performed to study the polymorphisms 
in patients.  For CYP3A4*1B, the method proposed 
by Cavalli, et al., 2001 (14) was used, which uses 
the following Forward and Reverse primers, 5´-
GGAATGAGGACAGCCATAGAGACAAGGGGA-3’ 
and 5´-CCTTTCAGCTCTGTGTTGCTCTTTGCTG 
-3’, respectively. These primers amplify the 5´ 
promoter region of the human gene CYP3A4 
(-318 to +6 nucleotides), producing a 385 bp 
length amplicon that contains the polymorphic 
(position 41) and constitutive (position 210) sites 
for the restriction enzyme MboII. After performing 
the PCR protocol, the amplicon was digested by 
MboII enzyme. Agarose 2.0% gel electrophoresis 
revealed 175 bp and 169 bp fragments of the wild 
type homozygous allele (*1/*1), 210 bp and 175 
bp fragments for the homozygous polymorphic 
genotype (*1B/*1B), and fragments of 210, 175 
and 169 bp for the heterozygous genotype (*1/*1B) 
(Figure 1A).
The polymorphism CYP3A5*3 was detected 
using the method proposed by Lee and 
Goldstein  (15), which consists of an amplification 
with the Forward and Reverse primers, 5’-
CTTTAAAGAGCTCTTTTGTCTCTCA-3’ and 5’-
Figure 1. Agarose gel electrophoresis showing CYP3A4 (A) and CYP3A5 (B) genotypes 
Table 1. Demographic characteristics and baseline data of 
hematological and biochemical parameters of 17 healthy adult 
female volunteers. 
 Mean SD Normal range
Age (years) 26.94 8.76 - 
Weight (kg) 59.56 7.23 - 
Height (cm) 160.32 6.42 - 
BMI 23.23 3.02 19-27  
Creatinine (g/L) 0.83 0.19 0.8-1.5 
Alkaline phosphatase (UI) 68.06 14.14 38.0-126.0 
Glucose (mg/dl) 83.55 9.49 60.0-100.0 
Uremia (mg/dl) 25.43 7.34 0.0-50.0 
AST (UI) 24.47 6.57 5.0-40.0 
ALT (UI) 17.71 6.95 7.0-56.0 
Hematocrite 38.11 1.96 40.0-54.0
Leukocytes (x µl) 6620.0 1204.7 5,000.0-10,000.0
Hemoglobin (mg/dl) 12.73 0.73 12.0-16.0 
Total bilirrubin 0.57 0.26 0.2-1.3
100 bp
200 bp
300 bp
210 bp
175 bp
169 bp
*1B/*1B wt/wtwt/*1B wt/wt
197 bp
162 bp
100 bp
200 bp
wt/wt *3/*3 wt/*3
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GAAGCCAGACTTTGATCATTATGTTATG-3’, 
respectively. A non-matching nucleotide was used 
(underlined) on the forward primer, four bases 
upstream of the 3´ end, to introduce an allele-specific 
restriction site for the BseMII enzyme. The protocol 
amplifies a fragment of intron 3 and produces a 197 
bp long amplicon. Agarose 3% gel electrophoresis 
revealed the same 197 bp fragments for wild-type 
homozygous subjects (*1/*1), as well as without 
digestion, two fragments of 162 bp and 35 bp for 
subjects homozygous for polymorphism *3/*3, and 
three fragments of 197 bp, 162 bp and 35 bp for the 
heterozygous genotype (*1/*3) (Figure 1B).
Pharmacokinetic study
After a 12-hour overnight fast, volunteers received 
a single oral dose of 0.75 mg of levonorgestrel 
(Postinor™, Gedeon Richter Laboratories, Budapest, 
Hungary, Lot N° T69476) with 250 mL of drinking 
water while standing.
Blood samples were obtained in a heparinised 
glass tube before dosing (0) and at 0.5, 1.0, 1.5, 
2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12 and 24 hours 
post dose. After centrifugation, plasma samples 
were stored in plastic tubes at –20°C until assayed. 
Levonorgestrel concentrations were determined by 
Ultra Performance Liquid Chromatography (UPLC) 
connected with a mass spectrometer ACQUITY 
integrated system of Waters for levonorgestrel 
(16,17). The method was validated in the laboratory 
and defined according to sensibility, specificity, 
linearity, recovery, detection limits, quantification, 
accuracy, precision and reproducibility (both intraday 
and interday) for levonorgestrel concentration 
ranges of 0.5 to 90 ng/mL in 0.5 mL of plasma. The 
internal	 standard	 was	 17-α-methyltestosterone	
(USP). Isolated plasma was defrosted and 1.0 mL 
was transferred to polypropylene tubes previously 
cleaned with methyl tert butyl ether (MTBE). Next, 5 
mL of isoamylic hexane/alcohol (90/10) were added 
to extract the drug. The mixture was vortex-mixed 
for one minute and then centrifuged at 1400 g for 5 
minutes. The sample was frozen, and the remaining 
liquid phase was evaporated by gaseous nitrogen, 
a process that takes between 15 to 20 minutes. 
Subsequently, the sample was reconstituted with the 
solvent used for the UPLC procedure (acetonitrile/
water 69:31 with 0.1% formic acid). The mixture 
was then vortex-mixed. Chromatography was 
performed using a UPLC Waters system connected 
with a mass spectrometer, combined with a C18 
(2.1 x 50 mm, 3 µ) Waters column. The mobile 
phases were acetonitrile/water 69:31 v/v with 0.1% 
formic acid, injected at a rate of 200 µl/min. The 
total elution time was 8.67 minutes.
The mass spectrometry was performed with a triple 
quadrupole mass spectrometry detector using 
electro spray ionisation for the mass analysis and 
detection. The mass spectrometric analysis was 
carried out in positive ion mode and arranged in the 
selective monitoring reaction mode. Based on all of 
the analytes’ mass spectrums, the most abundant 
ions were selected, and the spectrometer was 
subsequently arranged to monitor the transitions 
of m/z 312.7 and 303.2 ions to the product ions 
m/z 108.96	and	96.88	for	levonorgestrel	and	17-α-
methyltestosterone, respectively.
The following pharmacokinetic parameters were 
determined using the statistical computer’s program 
Stata 10.0: maximum plasmatic concentration 
(Cmax), maximum time (tmax), area under curve 
(AUC) of plasmatic concentrations from time zero 
to tmax and from 0 to infinity, half-life time (t1/2) and 
elimination constant (Ke).
Ethics
The study protocols, both for the pharmacokinetic 
stage and the pharmacogenetic stage, were 
submitted separately to the Ethics Committee 
for Studies on Human Beings of the Faculty of 
Medicine, University of Chile, which approved both 
the protocols and the Informed Consent document 
provided by the volunteers. Procedures employed 
were in accordance with the declaration of Helsinki 
and Good Clinical Practices of the FDA (18,19).
Statistical analysis
Statistical analysis was carried out with statistical 
program Stata 10. To relate pharmacokinetic data 
to the different studied genotypes, the Kruskal-
Wallis test was applied; this test applied a unilateral 
ANOVA of variation ranges, to each studied 
polymorphism, using a significance value of 0.05.
Results
All subjects successfully completed the study 
in accordance with the protocol. The genotype 
analysis of healthy volunteers unveiled the following 
results: for CYP3A4*1B, 14 were wild type (*1), 1 
heterozygous (*1/*1B) and 2 homozygous for the 
polymorphism (*1B/*1B); for CYP3A5*3 there was 
1 wild-type (*1/*1), 4 heterozygous (*1/*3) and 12 
homozygous for the polymorphism (*3/*3).
Demographic data showed no significant differences 
according to CYP3A4 and CYP3A5 genotype 
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(data no shown). The studied group had a 29.6% 
Amerindian-Caucasian admixture, determined using 
the method of Acuña, et al., 2000 (20).
The pharmacokinetic data of the volunteers 
according to their genotypes for CYP3A4 and 
CYP3A5 are shown on table 2.
Genotype frequencies for CYP3A4*1B were 11.8% 
for *1B/*1B, 5.8 % for *1/*1B and 82.4% for *1/*1. 
The allele frequency for *1B allele was 0.147.  For 
CYP3A5*3 polymorphism genotype frequencies 
were 70.5 % for *3/*3, 23.5 % for *1/*3 and 6.5% 
for *1/*1. The allele frequency for *3 was 0.824. 
Pharmacokinetic parameters separated by 
genotype are shown also in table 2 and figure 2. The 
statistical analysis show no significant differences 
in Cmax among volunteers with *1/*1, *1B/*1B and 
*1/*1B, or among any of the CYP3A5 genotypes. 
Discussion
CYP3A4*1B consists of a SNP present in the gene’s 
promoter region (-292) which seems to produce 
altered enzymatic activity. In vitro, it exhibits twice 
the activity compared to the wild-type genotype 
CYP3A4*1A (21), even though there are no in vivo 
studies showing that the CYP3A4*1B polymorphism 
is linked to a higher enzyme activity (22). Recently, 
Schirmer et al, 2007 (23) proposed a role for this 
polymorphism and other CYP3A variants on the 
catalytic activity of the enzyme. The authors try to 
reconcile the apparent contradiction between the 
evidence for the influence of the individual genetic 
makeup on CYP3A4 expression and activity 
suggested by clinical studies, and the failure to 
identify the responsible CYP3A gene variants. 
However, the studied CYP3A5 polymorphism 
(CYP3A5*3) is found in the intron 3 (6986 A>G) 
and produces a splice variant that originates in the 
aberrant exon 3B, which causes the introduction 
of a premature stop codon and leads to the 
translation of a non-functional truncated protein 
(24). This enzyme possesses a large structural 
and catalytic resemblance with CYP3A4, and even 
though it is unlikely that this enzyme is expressed 
in a polymorphic way in tissues, its contribution to 
the clearance of some drugs may be an important 
source of inter-individual variability (1,24,25). 
There are no reported studies regarding the role 
of the polymorphism CYP3A5*3 and levonorgestrel 
metabolism.
The allelic frequencies found in the healthy Chilean 
volunteers are similar to those reported within the 
Caucasian and Japanese populations (1,22,26), 
showing no relevant differences in our “mestizo” 
population in terms of the presence of the studied 
variants. This observation stands in opposition 
to other polymorphism for phase I and phase II 
biotransformation enzymes, in which we have been 
able to observe profound differences (26).
Because levonorgestrel is a substrate of the 
studied cytochromes (CYP3A4 and CYP3A5), 
we proposed that the studied polymorphism may 
have an effect on levonorgestrel pharmacokinetic 
parameters in healthy volunteers treated with a 
single, oral dose of the drug. Moreover, as it is well 
known these parameters also can be influenced 
by other factors such as physiological and 
pathological conditions, environmental exposure 
and interactions with other drugs, we strictly 
controlled health conditions. We ensured the 
volunteers did not consume any medication and 
Table 2. Pharmacokinetic data according to the CYP3A4 and CYP3A5 genotypes of 17 adult female healthy volunteers
 CYP3A4*1/*1       CYP3A4*1/*1B       CYP3A4*1B/*1B
Number of subjects 14 1 2 
Cmax (ng/ml) 16.35± 9.5 23.97 16.98± 1.6
T½ (hours) 23.91± 13.5 53,13 21.41± 5,8
AUC0Tmax (ng.h/ml) 110.13± 35.7 225.85 115.31± 33.0
AUC0infinite (ng.h/ml) 191.95± 16.1 724.58 205.47± 92.3
Ke (1/time in hours) 0.032± 0.016 0.010 0.04± 0.005                    
 CYP3A5*1/*1          CYP3A5*1/*3        CYP3A5*3/3
Number of subjects 1 4 12 
Cmax: ng/ml (SD) 18.51 22.90    (13.9) 14.20    (5.9)
T½ : hours (SD) 27.29 16.62   (4.6) 28.07   (15.7)
AUC0Tmax : ng.h/ml (SD) 148.34 204.08   (127.5) 86.13    (54.23)
AUC0infinite: ng.h/ml (SD) 297.80 309.59   (214.5) 190.56   (32.3)
Ke: 1/time in hours (SD) 0.02 0.04   (0.01) 0.027   (0.014)
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that they were not exposed to any environmental 
or alimentary relevant xenobiotics.
We used a validated UPLC MS/MS method to detect 
levonorgestrel similar to that usually employed in the 
detection of other progestagens and oestrogens. 
This method provides high instrument sensibility 
and, because we are looking for the parent drug 
and not the metabolite, we can observe LNG 
plasma levels to evaluate the bioavailability as an 
indication of the potential therapeutic effect.
The results showed no significant differences among 
the pharmacokinetic parameters analysed (Cmax, 
t1/2, AUC0tmax, AUC0infinite and Ke) for CYP3A4*1B 
and CYP3A5*3 polymorphisms in the studied 
group. This fact could be due to the small number 
of subjects in the current study.
To the best of our knowledge, this is a first study 
to look for a relationship between CYP3A4/5 
polymorphisms and pharmacokinetics of levonor-
gestrel. Thus, it could be a first approach to the 
personalised progestagen treatment based on 
pharmacogenetic profiles.
Despite the fact we were not able to demonstrate 
significant differences, the observation that 
volunteers have heterogeneous pharmacokinetic 
parameters in their individual pharmacokinetic 
curves (data not shown); additionally, the 
observations, based on the genotype-grouped 
curves (figure 2), provides supplemental tools for 
studying possible personalised pharmacotherapy. 
Undoubtedly, it is necessary to continue these 
investigations by carrying out studies with a larger 
number of volunteers.
Figure 2. Pharmacokinetic curves of volunteers based on CYP3A4*1B (A) and CYP3A5*3 (B) genotypes
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In combination with other studies, our study could 
help us to define the potential clinical use for 
therapeutics in populations containing genetic 
polymorphisms in CYP3A4 and CYP3A5 genes, 
such as the Amerindian-Caucasian admixtures 
observed in the Chilean population. Therefore, the 
data obtained might assist in our understanding of 
the inter-ethnic differences for not only single CYP3A 
polymorphisms but also the function of simultaneous 
CYP3A4/5 polymorphisms, and they may help 
explain the differences in the metabolic responses 
to levonorgestrel among different individuals.
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